Detalles de la búsqueda
1.
Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib.
Acta Derm Venereol
; 104: adv18452, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38708991
2.
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
J Eur Acad Dermatol Venereol
; 38(2): 340-353, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37669868
3.
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
J Am Acad Dermatol
; 89(3): 478-485, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37230366
4.
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
J Eur Acad Dermatol Venereol
; 37(12): 2558-2568, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37528500
5.
Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.
Acta Derm Venereol
; 98(10): 932-937, 2018 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30085324
6.
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.
J Dermatolog Treat
; 35(1): 2344589, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38697950
7.
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Dermatol Ther (Heidelb)
; 14(5): 1127-1144, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696027
8.
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Am J Clin Dermatol
; 25(3): 485-496, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38528257
9.
Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
Curr Med Res Opin
; 39(10): 1289-1296, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37691437
10.
Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis.
Dermatol Ther (Heidelb)
; 13(10): 2247-2264, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37658223
11.
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis.
Dermatitis
; 2023 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38108653
12.
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
JAMA Dermatol
; 159(5): 526-535, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37043227
13.
Contextualizing an expanded definition of health literacy among adolescents in the health care setting.
Health Educ Res
; 27(6): 961-74, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22623619
14.
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS).
Dermatol Ther (Heidelb)
; 12(12): 2817-2827, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36333616
15.
Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis.
Dermatol Ther (Heidelb)
; 12(5): 1181-1196, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35435637
16.
Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database.
Adv Ther
; 39(6): 2502-2514, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35352308
17.
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
JAMA Dermatol
; 158(4): 404-413, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35262646
18.
Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes.
J Med Econ
; 24(1): 1280-1289, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34816787
19.
The impact of uncontrolled asthma on absenteeism and health-related quality of life.
J Asthma
; 46(9): 861-6, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19905909
20.
Correction to: Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database.
Adv Ther
; 39(9): 4392-4393, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35904723
Resultados
1 -
20
de 20
1
Próxima >
>>